{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T23:42:10Z","timestamp":1769298130153,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T00:00:00Z","timestamp":1249948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s11912-009-0049-8","type":"journal-article","created":{"date-parts":[[2009,8,10]],"date-time":"2009-08-10T05:01:07Z","timestamp":1249880467000},"page":"363-370","source":"Crossref","is-referenced-by-count":6,"title":["Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma"],"prefix":"10.1007","volume":"11","author":[{"given":"Waleed","family":"Alduaij","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim M.","family":"Illidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,11]]},"reference":[{"key":"49_CR1","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMe048101","volume":"350","author":"M.R. Green","year":"2004","unstructured":"Green MR: Targeting targeted therapy. N Engl J Med 2004, 350:2191\u20132193.","journal-title":"N Engl J Med"},{"key":"49_CR2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P. McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"49_CR3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B. Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235\u2013242.","journal-title":"N Engl J Med"},{"key":"49_CR4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H. Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, et al.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706\u2013714.","journal-title":"J Natl Cancer Inst"},{"key":"49_CR5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"S.J. Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med 1984, 311:1471\u20131475.","journal-title":"N Engl J Med"},{"key":"49_CR6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1053-4296(00)80045-4","volume":"10","author":"S.J. Knox","year":"2000","unstructured":"Knox SJ, Meredith RF: Clinical radioimmunotherapy. Semin Radiat Oncol 2000, 10:73\u201393.","journal-title":"Semin Radiat Oncol"},{"key":"49_CR7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2000.01926.x","volume":"108","author":"T.M. Illidge","year":"2000","unstructured":"Illidge TM, Johnson PWM: The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol 2000, 108:679\u2013688.","journal-title":"Br J Haematol"},{"key":"49_CR8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0167-8140(84)80074-2","volume":"2","author":"J. Deacon","year":"1984","unstructured":"Deacon J, Peckham MJ, Steel GG: The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 1984, 2:317\u2013323.","journal-title":"Radiother Oncol"},{"issue":"Suppl14","key":"49_CR9","first-page":"58","volume":"5","author":"O.W. Press","year":"1999","unstructured":"Press OW: Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999, 5(Suppl 14):58\u201365.","journal-title":"Semin Oncol"},{"key":"49_CR10","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"R.L.M. Haas","year":"2003","unstructured":"Haas RLM, Poortmans P, de Jong D, et al.: High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003, 21:2474\u20132480.","journal-title":"J Clin Oncol"},{"key":"49_CR11","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","volume":"14","author":"M.P. Mac Manus","year":"1996","unstructured":"Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996, 14:1282\u20131290.","journal-title":"J Clin Oncol"},{"key":"49_CR12","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"T.E. Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002, 20:3262\u20133269.","journal-title":"J Clin Oncol"},{"key":"49_CR13","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"T.E. Witzig","year":"2002","unstructured":"Witzig TE, White CA, Gordon LI, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002, 20:2453\u20132463.","journal-title":"J Clin Oncol"},{"key":"49_CR14","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"M.S. Kaminski","year":"2001","unstructured":"Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I 131 tositumomab for chemotherapyrefractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas. J Clin Oncol 2001, 19:3918\u20133928.","journal-title":"J Clin Oncol"},{"key":"49_CR15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","volume":"23","author":"S.J. Horning","year":"2005","unstructured":"Horning SJ, Younes A, Jain V, et al.: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005, 23:712\u2013719.","journal-title":"J Clin Oncol"},{"key":"49_CR16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","volume":"47","author":"C. Emmanouilides","year":"2006","unstructured":"Emmanouilides C, Witzig TE, Gordon LI, et al.: Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 2006, 47:629\u2013636.","journal-title":"Leuk Lymphoma"},{"key":"49_CR17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"M.S. Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441\u2013449.","journal-title":"N Engl J Med"},{"key":"49_CR18","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","volume":"23","author":"J.P. Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Kostakoglu L, et al.: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005, 23:5696\u20135704.","journal-title":"J Clin Oncol"},{"key":"49_CR19","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","volume":"102","author":"O.W. Press","year":"2003","unstructured":"Press OW, Unger JM, Braziel RM, et al.: A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003, 102:1606\u20131612.","journal-title":"Blood"},{"issue":"14Suppl","key":"49_CR20","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1200\/jco.2004.22.14_suppl.6520","volume":"22","author":"B. Link","year":"2004","unstructured":"Link B, Kaminski MS, Coleman M, Leonard JP: Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin\u2019s lymphoma (NHL) [abstract]. J Clin Oncol 2004, 22(14 Suppl):6520.","journal-title":"J Clin Oncol"},{"key":"49_CR21","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F. Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, et al.: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26:5156\u20135164.","journal-title":"J Clin Oncol"},{"key":"49_CR22","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","volume":"103","author":"L.I. Gordon","year":"2004","unstructured":"Gordon LI, Molina A, Witzig T, et al.: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study. Blood 2004, 103:4429\u20134431.","journal-title":"Blood"},{"key":"49_CR23","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","volume":"23","author":"R.I. Fisher","year":"2005","unstructured":"Fisher RI, Kaminski MS, Wahl RL, et al.: Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas. J Clin Oncol 2005, 23:7565\u20137573.","journal-title":"J Clin Oncol"},{"key":"49_CR24","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","author":"T.E. Witzig","year":"1999","unstructured":"Witzig TE, White CA, Wiseman GA, et al.: Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 1999, 17:3793\u20133803.","journal-title":"J Clin Oncol"},{"key":"49_CR25","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"T.E. Witzig","year":"2003","unstructured":"Witzig TE, White CA, Gordon LI, et al.: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 2003, 21:1263\u20131270.","journal-title":"J Clin Oncol"},{"key":"49_CR26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1089\/cbr.2007.359","volume":"22","author":"C. Emmanouilides","year":"2007","unstructured":"Emmanouilides C, Witzig TE, Wiseman GA, et al.: Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin\u2019s lymphoma. Cancer Biother Radiopharm 2007, 22:684\u2013691.","journal-title":"Cancer Biother Radiopharm"},{"key":"49_CR27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","volume":"110","author":"F. Morschhauser","year":"2007","unstructured":"Morschhauser F, Illidge T, Huglo D, et al.: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007, 110:54\u201358.","journal-title":"Blood"},{"key":"49_CR28","first-page":"2452","volume":"106","author":"A. Younes","year":"2005","unstructured":"Younes A, Pro B, Rodriguez MA, et al.: Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]. ASH Annual Meeting Abstracts 2005, 106:2452.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"49_CR29","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","volume":"16","author":"S.Y. Liu","year":"1998","unstructured":"Liu SY, Eary JF, Petersdorf SH, et al.: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998, 16:3270\u20133278.","journal-title":"J Clin Oncol"},{"key":"49_CR30","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","volume":"96","author":"O.W. Press","year":"2000","unstructured":"Press OW, Eary JF, Gooley T, et al.: A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000, 96:2934\u20132942.","journal-title":"Blood"},{"key":"49_CR31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","volume":"26","author":"A. Krishnan","year":"2008","unstructured":"Krishnan A, Nademanee A, Fung HC, et al.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol 2008, 26:90\u201395.","journal-title":"J Clin Oncol"},{"key":"49_CR32","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","volume":"27","author":"J.N. Winter","year":"2009","unstructured":"Winter JN, Inwards DJ, Spies S, et al.: Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2009, 27:1653\u20131659.","journal-title":"J Clin Oncol"},{"issue":"16Suppl","key":"49_CR33","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1200\/jco.2005.23.16_suppl.6577","volume":"23","author":"D.L. Shipley","year":"2005","unstructured":"Shipley DL, Greco FA, Spigel DR, et al.: Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial [abstract]. J Clin Oncol 2005, 23(16 Suppl):6577.","journal-title":"J Clin Oncol"},{"key":"49_CR34","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","volume":"14","author":"S.A. Jacobs","year":"2008","unstructured":"Jacobs SA, Swerdlow SH, Kant J, et al.: Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008, 14:7088\u20137094.","journal-title":"Clin Cancer Res"},{"key":"49_CR35","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood-2008-11-188896","volume":"113","author":"R.M. Sharkey","year":"2009","unstructured":"Sharkey RM, Press OW, Goldenberg DM: A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody\/radioantibody therapy. Blood 2009, 113:3891\u20133895.","journal-title":"Blood"},{"key":"49_CR36","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2008-01-132142","volume":"112","author":"A.K. Gopal","year":"2008","unstructured":"Gopal AK, Press OW, Wilbur SM, et al.: Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008, 112:830\u2013835.","journal-title":"Blood"},{"key":"49_CR37","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","volume":"113","author":"T.M. Illidge","year":"2009","unstructured":"Illidge TM, Bayne M, Brown NS, et al.: Phase 1\/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009, 113:1412\u20131421.","journal-title":"Blood"},{"key":"49_CR38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","volume":"100","author":"K. Tobinai","year":"2009","unstructured":"Tobinai K, Watanabe T, Ogura M, et al.: Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009, 100:158\u2013164.","journal-title":"Cancer Sci"},{"key":"49_CR39","first-page":"2747","volume":"108","author":"W. Jurczak","year":"2006","unstructured":"Jurczak W, Giza A, Szostek M, et al.: 90Y-Zevalin(R) (90Y-ibritumomab tiuxetan) radioimmunotherapy (RIT) consolidation of FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: results from the PLRG upon completed enrollment [abstract]. ASH Annual Meeting Abstracts 2006, 108:2747.","journal-title":"ASH Annual Meeting Abstracts"},{"key":"49_CR40","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/jco.2006.24.18_suppl.7503","volume":"24","author":"M.R. Smith","year":"2006","unstructured":"Smith MR, Chen H, Gordon L, et al.: Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1499) [abstract]. J Clin Oncol (Meeting Abstracts) 2006, 24:7503.","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"49_CR41","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"M.H.J. Oers van","year":"2006","unstructured":"van Oers MHJ, Klasa R, Marcus RE, et al.: Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295\u20133301.","journal-title":"Blood"},{"key":"49_CR42","first-page":"926","volume":"106","author":"P.A. Hamlin","year":"2005","unstructured":"Hamlin PA, Moskowitz CH, Wegner BC, et al.: Early safety and efficacy analysis of a phase II study of sequential RCHOP and yttrium-90 ibritumomab tiuxetan (Zevalin) for elderly high risk patients with untreated DLBCL [abstract]. ASH Annual Meeting Abstracts 2005, 106:926.","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-009-0049-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-009-0049-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-009-0049-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T09:03:51Z","timestamp":1590051831000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-009-0049-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1007\/s11912-009-0049-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,11]]}}}